Ovarian Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Ovarian Cancer - Pipeline Review, H1 2016

Ovarian Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Ovarian Cancer - Pipeline Review, H1 2016
Published Jun 28, 2016
1780 pages — Published Jun 28, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Ovarian Cancer - Pipeline Review, H1 2016, provides an overview of the Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
- The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects
- The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop an

  
Source:
Document ID
GMDHC7956IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents263
  List of Tables559
  List of Figures641
Introduction651
  Global Markets Direct Report Coverage651
Ovarian Cancer Overview661
Therapeutics Development672
  Pipeline Products for Ovarian Cancer Overview671
  Pipeline Products for Ovarian Cancer Comparative Analysis681
Ovarian Cancer Therapeutics under Development by Companies6922
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes913
Ovarian Cancer Pipeline Products Glance944
  Late Stage Products941
  Clinical Stage Products951
  Early Stage Products961
  Unknown Stage Products971
Ovarian Cancer Products under Development by Companies9829
Ovarian Cancer Products under Investigation by Universities/Institutes1274
Ovarian Cancer Companies Involved in Therapeutics Development131271
  3-V Biosciences, Inc.1311
  4SC AG1321
  AB Science SA1331
  AbbVie Inc.1341
  AbGenomics International, Inc.1351
  Acetylon Pharmaceuticals, Inc.1361
  Adaptimmune Therapeutics Plc1371
  Adgero Biopharmaceuticals, Inc.1381
  Aduro BioTech, Inc.1391
  Advanced Accelerator Applications S.A.1401
  Advantagene, Inc.1411
  Advaxis, Inc.1421
  Advenchen Laboratories, LLC1431
  Aeterna Zentaris Inc.1441
  Alchemia Limited1451
  Alethia Biotherapeutics Inc.1461
  Almac Discovery Limited1471
  Alpha Cancer Technologies Inc.1481
  Alteogen Inc.1491
  Ambrx, Inc.1501
  Amgen Inc.1511
  Anavex Life Sciences Corp.1521
  ANP Technologies, Inc.1531
  Antoxis Limited1541
  Apac Biotech Pvt Ltd1551
  Aphios Corporation1561
  Aposense Ltd.1571
  Aprea AB1581
  arGEN-X BV1591
  Armour Therapeutics Inc.1601
  Arno Therapeutics, Inc.1611
  Arog Pharmaceuticals, Inc.1621
  ArQule, Inc.1631
  Arrien Pharmaceuticals, LLC1641
  Arvinas, Inc.1651
  Ascentage Pharma Group Corporation, Ltd.1661
  Astellas Pharma Inc.1671
  Astex Pharmaceuticals, Inc.1681
  AstraZeneca Plc1691
  Atara Biotherapeutics, Inc.1701
  ATLAB Pharma SAS1711
  AVEO Pharmaceuticals, Inc.1721
  Avipep Pty Ltd1731
  Azaya Therapeutics, Inc.1741
  Basilea Pharmaceutica AG1751
  Bavarian Nordic A/S1761
  Bayer AG1771
  BeiGene, Ltd.1781
  BioCancell Ltd1791
  BioMoti Limited1801
  BioNTech AG1811
  BioNumerik Pharmaceuticals, Inc.1821
  Bioo Therapeutics1831
  Biscayne Pharmaceuticals, Inc.1841
  Boehringer Ingelheim GmbH1851
  Boston Biomedical, Inc.1861
  Bristol-Myers Squibb Company1871
  Calithera Biosciences, Inc.1881
  CASI Pharmaceuticals Inc.1891
  Cavion LLC1901
  Cellceutix Corporation1911
  Celldex Therapeutics, Inc.1921
  Cellectar Biosciences, Inc.1931
  Cellular Biomedicine Group, Inc.1941
  Celon Pharma Sp. z o.o.1951
  Celprogen, Inc.1961
  Celsion Corporation1971
  Celyad SA1981
  Ceronco Biosciences1991
  CerRx, Inc.2001
  Cerulean Pharma, Inc.2011
  Chikujee Therapeutics2021
  Chipscreen Biosciences Ltd2031
  Clovis Oncology, Inc.2041
  CohBar, Inc.2051
  Coherus BioSciences, Inc.2061
  Commence Bio, Inc.2071
  Compliment Corporation2081
  Corcept Therapeutics Incorporated2091
  Critical Outcome Technologies Inc.2101
  CritiTech, Inc.2111
  CTI BioPharma Corp.2121
  Cyclacel Pharmaceuticals, Inc.2131
  CytRx Corporation2141
  CZ BioMed Corp2151
  Debiopharm International SA2161
  Deciphera Pharmaceuticals, LLC2171
  DEKK-TEC, Inc.2181
  DelMar Pharmaceuticals, Inc.2191
  Dr. Reddy's Laboratories Limited2201
  EirGenix Inc.2211
  Eisai Co., Ltd.2221
  Eli Lilly and Company2231
  Endocyte, Inc.2241
  EntreChem, S.L.2251
  Epigen Biosciences, Inc.2261
  Esperance Pharmaceuticals, Inc.2271
  Exelixis, Inc.2281
  F. Hoffmann-La Roche Ltd.2291
  Fate Therapeutics, Inc.2301
  Forty Seven Inc.2311
  Fujifilm Corporation2321
  Galena Biopharma, Inc.2331
  GamaMabs Pharma S.A.2341
  Ganymed Pharmaceuticals AG2351
  Gene Techno Science Co., Ltd.2361
  Genelux Corporation2371
  Genentech, Inc.2381
  Generex Biotechnology Corporation2391
  Genisphere Inc.2401
  Genmab A/S2411
  Genor BioPharma Co., Ltd.2421
  Gero Corp2431
  Gilead Sciences, Inc.2441
  GlaxoSmithKline Plc2451
  Glenmark Pharmaceuticals Ltd.2461
  GlycoNex Inc.2471
  Glycotope GmbH2481
  GP Pharm, S.A.2491
  Gradalis Inc.2501
  GW Pharmaceuticals Plc2511
  Halozyme Therapeutics, Inc.2521
  HEC Pharm Co., Ltd.2531
  Hemispherx Biopharma, Inc.2541
  Horizon Pharma Plc2551
  Ideaya Biosciences Inc2561
  Ignyta, Inc.2571
  IMMD Inc.2581
  Immune Design Corp.2591
  Immune Pharmaceuticals Inc.2601
  ImmunoFrontier, Inc.2611
  ImmunoGen, Inc.2621
  Immunomedics, Inc.2631
  Immunovaccine, Inc.2641
  Incyte Corporation2651
  Inflection Biosciences Limited2661
  Innate Immunotherapeutics Ltd2671
  Innate Pharma S.A.2681
  Inovio Pharmaceuticals, Inc.2691
  INSYS Therapeutics, Inc.2701
  Inventiva2711
  Jiangsu Kanion Pharmaceutical Co., Ltd.2721
  Johnson &Johnson2731
  Juno Therapeutics Inc.2741
  Karyopharm Therapeutics, Inc.2751
  Komipharm International Co., Ltd.2761
  Kyowa Hakko Kirin Co., Ltd.2771
  Laboratoire HRA Pharma2781
  Lee's Pharmaceutical Holdings Limited2791
  LegoChem Biosciences, Inc2801
  Lymphocyte Activation Technologies, S.A.2811
  Mabion SA2821
  MabVax Therapeutics Holdings, Inc.2831
  MacroGenics, Inc.2841
  Mateon Therapeutics Inc2851
  MaxiVAX SA2861
  Mebiopharm Co., Ltd.2871
  Medestea Research &Production S.p.A.2881
  MediaPharma s.r.l.2891
  MedImmune, LLC2901
  Medivation, Inc.2911
  MEI Pharma, Inc.2921
  Merck &Co., Inc.2931
  Merck KGaA2941
  Mersana Therapeutics, Inc.2951
  Merus B.V.2961
  Midatech Pharma Plc2971
  Millennium Pharmaceuticals, Inc.2981
  Minerva Biotechnologies Corporation2991
  Molecular Partners AG3001
  MolMed S.p.A.3011
  Momenta Pharmaceuticals, Inc.3021
  Monopar Therapeutics LLC3031
  Morphotek, Inc.3041
  Mundipharma International Ltd3051
  Mycenax Biotech Inc.3061
  Natco Pharma Limited3071
  Nektar Therapeutics3081
  Nemucore Medical Innovations, Inc.3091
  Neovacs SA3101
  Nerviano Medical Sciences S.r.l.3111
  Neurimmune Holding AG3121
  Northwest Biotherapeutics, Inc.3131
  Novartis AG3141
  NovaTarg Therapeutics, Inc3151
  Noviga Research AB3161
  NuCana BioMed Limited3171
  Oasmia Pharmaceutical AB3181
  OBI Pharma, Inc.3191
  Omeros Corporation3201
  Omnitura Therapeutics Inc.3211
  OncBioMune Pharmaceuticals Inc.3221
  Oncobiologics, Inc.3231
  Oncodesign SA3241
  OncoHoldings, Inc.3251
  Oncolix, Inc.3261
  Oncolytics Biotech Inc.3271
  OncoMed Pharmaceuticals, Inc.3281
  Oncopeptides AB3291
  OncoTartis, Inc.3301
  Oncternal Therapeutics, Inc.3311
  Ono Pharmaceutical Co., Ltd.3321
  Optimum Therapeutics, LLC3331
  ORCA Therapeutics B.V.3341
  OSE Immunotherapeutics3351
  Otsuka Holdings Co., Ltd.3361
  Oxford BioMedica Plc3371
  Pangaea Biotech, S.L.3381
  Panther Biotechnology, Inc.3391
  PDS Biotechnology Corporation3401
  PEP-Therapy SAS3411
  Pfizer Inc.3421
  Pharma Mar, S.A.3431
  Pharmacyclics, Inc.3441
  PharmAust Limited3451
  Pharmicell Co., Ltd.3461
  Polaris Pharmaceuticals, Inc.3471
  Precision Biologics, Inc.3481
  Prima BioMed Ltd.3491
  Progen Pharmaceuticals Limited3501
  PsiOxus Therapeutics Limited3511
  Puma Biotechnology, Inc.3521
  Quest PharmaTech Inc.3531
  Recepta Biopharma S.A.3541
  Rexahn Pharmaceuticals, Inc.3551
  Rgenix, Inc.3561
  Richter Gedeon Nyrt.3571
  Rigontec GmbH3581
  Rosetta Genomics, Ltd.3591
  Sanofi3601
  Sanofi Pasteur SA3611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Ovarian Cancer - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ovarian-Cancer-Pipeline-Review-H1-2016-2088-16016>
  
APA:
Global Markets Direct - Market Research. (2016). Ovarian Cancer - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ovarian-Cancer-Pipeline-Review-H1-2016-2088-16016>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.